Citations

Clear

264 citation(s) found for "Ellis, ED".

Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer
Symmans, W. Fraser , Chen, Yunn-Yi, Klein, Molly, Nanda, Rita , Parker, Barbara A. , Datnow, Brian, Krings, Gregor , Wei, Shi , Duan, Xiuzhen, Chen, Beiyun, Sattar, Husain, Khazai, Laila , Zeck, Jay , Sams, Sharon B. , Mhawech‐Fauceglia, Paulette , Rendi, Mara H. , Sahoo, Sunati , Ocal, Idris Tolgay, Fan, Fang, LeBeau, Lauren, Vinh, Tuyethoa N., Troxell, Megan L. , Chien, A. Jo , Forero‐Torres, Andres , Ellis, Erin D. , Albain, Kathy S. , Liu, Minetta C. , Haley, Barbara , Clark, Amy S. , Kemmer, Kathleen, Lang, Julie E. , Edmiston, Kirsten K., Viscusi, Rebecca K., Northfelt, Donald W. , Khan, Qamar J. , Leyland‐Jones, Brian , Venters, Sara J., Shad, Sonal , Matthews, Jeffrey B. , Asare, Smita , Buxton, Meredith , Asare, Adam L. , Schwab, Richard B. , Veer, Laura van ‘t , Perlmutter, Jane , Yee, Douglas , Berry, Donald A. , Esserman, Laura J. , Symmans, W Fraser , Esserman, Laura J , Asare, Adam L , Yee, Douglas , Yau, Christina , Chen, Yunn‐Yi , Balassanian, Ronald , Pusztai, Lajos , Feldman, Michael D. , Wallace, Anne M. , Murthy, Rashmi Krishna , Boughey, Judy C. , Elias, Anthony , Isaacs, Claudine , Han, Hyo S , Matthews, Jeffrey B., Rugo, Hope S. , Helsten, Teresa L. , Hylton, Nola M. , Veer, Laura J. van’t , DeMichele, Angela

Mayo Clinic

JAMA Oncology | September 16, 2021 | Volume: 7 | Issue: 11 | Pages: 1654

10.1001/jamaoncol.2021.3690 | PMID 34529000 Get It

Structure of an AMPK complex in an inactive, ATP-bound state
Yan, Yan , Mukherjee, Somnath , Harikumar, Kaleeckal G. , Strutzenberg, Timothy S. , Zhou, X. Edward , Suino-Powell, Kelly, Xu, Ting-Hai , Sheldon, Ryan D. , Lamp, Jared , Brunzelle, J.S. , Radziwon, Katarzyna, Novick, Scott J. , Vega, Irving E. , Xu, H. Eric , Griffin, Patrick R. , Kossiakoff, Anthony A. , Melcher, Karsten , Brunzelle, Joseph S , Ellis, Abigail , Novick, Scott J , Jones, Russell G , Miller, Laurence J , Xu, H Eric , Griffin, Patrick R , Melcher, Karsten , Harikumar, Kaleeckal G , Jones, Russell G. , Miller, Laurence J.

Mayo Clinic

Science | July 22, 2021 | Volume: 373 | Issue: 6553 | Pages: 413-419

10.1126/science.abe7565 | PMID 34437114 Get It

How to catch a dynamic state AMP-activated protein kinase (AMPK) is a key sensor of energy status in eukaryotes. Its dynamic structure is regulated by allosteric factors including phosphorylation and binding of nucleotides and metabolites. Yan et al. developed conformation-specific antibodies that trap AMPK in a fully inactive state that has experienced a large, domain-level rotation. Biophysical experiments in cells and in vitro are consistent with the structural work and support a model in which the activation loop is fully exposed in the completely inactive, dephosphorylated state. These structures inform our understanding of the complex allosteric behavior in this crucial metabolic regulator. Science , abe7565, this issue p. 413
Abstract CT026: A phase II trial of neratinib (NER) or NER plus fulvestrant (FUL) (N+F) in HER2 mutant, non-amplified (HER2mut) metastatic breast cancer (MBC): Part II of MutHER
Cynthia, X. , Nangia, Julie R. , Lu, Janice , Valdez-Albini, Frances, Jones, Jason M. , Thomas, Shana , Anderson, J. L. , Haas, Brittney , Hamann, Kimberly M., Bryce, Richard , Lalani, Alshad S. , Kimmick, Gretchen , Pegram, Mark D. , Bose, Ron , Luo, Jingqin , Freedman, Rachel A. , Pluard, Timothy , Cobleigh, Melody , Lin, Nancy U. , Winer, Eric P. , Marcom, Paul Kelly , Anderson, Jill, Carey, Lisa A. , Goetz, Matthew P. , Gao, Feng , Ellis, Matthew J.

Mayo Clinic

Cancer Research | July 1, 2021 | Volume: 81 | Issue: 13_Supplement | Pages: CT026-CT026

10.1158/1538-7445.am2021-ct026 Get It

Abstract Introduction: The irreversible pan-HER inhibitor NER showed modest single agent activity for HER2mut MBC in Part I of MutHER trial. In Part II, we hypothesized that (1) N+F would improve activity in estrogen receptor positive (ER+) HER2mut MBC due to ER-HER2 crosstalk and (2) dual HER2 blockade by adding trastuzumab at disease progression (PD) could overcome resistance. Methods: Pts with ER+HER2mut MBC were enrolled to 2 cohorts (FUL treated or naive) to receive N+F with diarrhea prophylaxis. ER- pts received NER in an exploratory ER- cohort. Trastuzumab was added at PD if approved by insurance. Simon's Minimax 2-stage phase II design with the primary endpoint of clinical benefit rate (CBR: rates of complete/partial response [CR/PR] plus stable disease [SD] >24 weeks [wks]), with anticipated vs null hypothesis being CBR of 55% vs 35% (FUL treated) or 65% vs 40% (FUL naïve) with 80% power, 1 sided 0.05 alpha, was used. Secondary endpoints included progression free survival (PFS) and adverse events (AEs). Serial blood samples were analyzed for circulating tumor DNA (ctDNA) by Guardant360 for concomitant mutations, HER2mut variant allele frequency (VAF) dynamics, and resistance mechanisms. Results: Between Sep. 2015 and Oct. 2020, 40 pts with HER2mut MBC were enrolled, completing the 1st stage of each ER+ cohort. 35 pts (21 FUL treated, 10 FUL naïve, 4 ER-) were evaluable for response, with median age 63 (35-82) years, 3 (0-12) prior MBC regimen, lobular BC in 13 (37%) and visceral mets in 32 (91%) pts. 21 (68%) ER+ pts had prior CDK4/6 inhibitor. All but 1 pt has come off study due to PD. Table 1 shows the efficacy by cohort. Further enrollment is closed per protocol. Adding trastuzumab at PD induced CB in 4 (3 PR, 1 SD≥24 wks) of 5 pts (1 ER-, 4 ER+), with PFS 28 (95% CI 18~NA) wks. Common AEs across cohorts were diarrhea (G3 21%) and fatigue (G3 5%). No G4 AEs. ctDNA HER2mut was detected in 72% (23/32) baseline (BL) samples tested. In pts with paired samples, HER2mut VAF decreased at C1D15/C2D1 from BL in 75% (15/20) and rose in 89% (16/18) at PD. Acquired HER2mut, including the T798I gatekeeper mutation, were detected in 2 pts at PD. Mutations in TP53 (53%), PIK3CA (43%), and CDH1 (35%) were common, but none significantly associated with PFS in all or ER+ pts. Conclusions: NER, or N+F, is active for HER2mut MBC with good tolerability. Adding trastuzumab at PD induced further response, supporting dual HER2 blockade for HER2mut MBC. Table 1.EfficacyCohortFUL treatedFUL naïveER-Best Response, n evaluablen = 21n = 10n = 4CR, n100PR, n431SD (≥ 24 wks), n300SD (< 24 wks), n1030PD, n343CBR, n with CB/total n evaluable, % (95% CI)8 of 20*, 40% (19~64%)3 of 10, 30% (7~65%)1 of 4, 25% (0.6~81%)mPFS (95% CI), wks, ITT (n)24 (16~31) wks, (n = 24)20 (8~NA) wks, (n = 11)8.5 (8~NA) wks, (n = 5)*20 of 21 pts are evaluable for CBR in the FUL treated Cohort as 1 pt had SD as best response and treatment is still ongoing. ITT (intent to treat) population is used for mPFS estimate. Citation Format: Cynthia X. Ma, Jingqin Luo, Rachel A. Freedman, Timothy Pluard, Julie Nangia, Janice Lu, Frances Valdez-Albini, Melody Cobleigh, Jason Jones, Nancy U. Lin, Eric Winer, P. Kelly Marcom, Shana Thomas, Jill Anderson, Brittney Haas, Kimberly M. Hamann, Richard Bryce, Alshad S. Lalani, Lisa Carey, Matthew Goetz, Feng Gao, Gretchen Kimmick, Mark Pegram, Matthew J. Ellis, Ron Bose. A phase II trial of neratinib (NER) or NER plus fulvestrant (FUL) (N+F) in HER2 mutant, non-amplified (HER2mut) metastatic breast cancer (MBC): Part II of MutHER [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr CT026.
SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691).
Hussain, Maha , Gupta, Shilpa , Plets, Melissa , Lara, Primo N. , Harzstark, Andrea, Twardowski, Przemyslaw, Zylla, Dylan M. , Zibelman, Matthew R. , Levine, Ellis , Roth, Bruce J. , Goldkorn, Amir , Vaena, Daniel A. , Crispino, Tony, Hussain, Maha H A , Agarwal, Neeraj , Tangen, Catherine M. , Paller, Channing J. , Zylla, Dylan , Kohli, Manish , Vogelzang, Nicholas J. , Thompson, Ian M. , Quinn, David I

Mayo Clinic

Journal of Clinical Oncology | June 2, 2021 | Volume: 39 | Issue: 15_suppl | Pages: 5001-5001

10.1200/jco.2021.39.15_suppl.5001 Get It

5001 Background: Tak is an oral selective nonsteroidal 17, 20-lyase inhibitor that blocks the synthesis of gonadal and adrenal androgens. We evaluated the clinical benefit of Tak with ADT in pts with newly diagnosed mHSPC. Methods: Pts with mHSPC with a Zubrod performance status (PS) of 0-2 and a PSA of ≥ 2 ng/ml were randomized 1:1 to ADT+Tak (300 mg twice daily) or ADT+Bic (50 mg daily). Stratification factors included PS (0-1 vs ≥2), extent of disease (minimal vs extensive), and receipt of ADT prior to registration (yes vs no). The primary endpoint was overall survival (OS). Secondary endpoints were progression free survival (PFS; based on PSA, imaging or clinical progression), PSA at 7 months (≤0.2 vs 0.2 < PSA; ≤-4 vs. > 4 ng/ml) and adverse event (AE) profile. With 2.75 yrs to accrue 1,186 eligible pts and 3 additional yrs of follow-up, we would have 90% power to determine a 33% improvement in OS from 54 to 72 mos (1-sided α = 0.025). A final analysis was pre-specified after 523 deaths using a 1-sided α = 0.022 to account for interim analyses. Results: Between 3/2013 and 7/2017, 1,313 pts were randomized and 1,279 were included in the intention-to-treat (ITT) analysis (32 pts were ineligible and 2 pts withdrew consent). Median age was 68 yrs and 10% of subjects were Black. Median PSA was 30 ng/mL (range 2-6710) and 49% of pts had extensive disease. After a median follow-up of 4.9 yrs, PFS and PSA response were significantly improved with Tak over Bic but no significant improvement in OS was observed (Table). More grade 3/4 AEs occurred in Tak vs. Bic arms (43% vs. 14%), and included hypertension (20% vs. 5%) and fatigue (5% vs. 2%). Five pts in Tak and 1 pt in the Bic arm had grade 5 AE. Conclusions: Despite clinically meaningful improvement in various outcome measures with Tak+ADT over Bic+ADT in this representative population of mHSPC, the improvement in OS did not meet the pre-specified criteria for statistical significance. The median OS of 70 mos in the control arm (standard ADT) was higher than that reported in contemporary phase 3 trials in this setting, and 16 mos higher than originally estimated. This trial sets a new landmark for survival estimates when pts with mHSPC have access to multiple approved subsequent life-prolonging therapies. Funding: NIH/NCI/NCTN grants U10CA180888, U10CA180819, U10CA180820; U10CA180821; and in part by Millennium Pharmaceuticals, Inc. (Takeda Pharmaceutical Company LTD) Clinical trial information: NCT01809691. [Table: see text]
Evaluation of sensitivity to endocrine therapy index (SET2,3) for response to neoadjuvant endocrine therapy (NET) and subsequent prognosis.
Du, Lili, Cynthia, X. , Symmans, W. Fraser , Hoskin, Tanya L. , Anurag, Meenakshi , Bedrosian, Isabelle , Hunt, Kelly K. , Ellis, Matthew J. , Suman, Vera J.

Mayo Clinic

Journal of Clinical Oncology | June 2, 2021 | Volume: 39 | Issue: 15_suppl | Pages: 580-580

10.1200/jco.2021.39.15_suppl.580 Get It

580 Background: Patients (pts) in Cohort A of the American College of Surgeons Oncology Group Z1031 (Alliance) trial of NET for cStage II-III breast cancer were randomized to anastrozole [ANA], letrozole [LET] or exemestane [EXE] for 16-18 weeks (wks). In Cohort B, pts chose between ANA and LET and switched to chemotherapy or surgery if a tumor biopsy after 2-4 wks of NET had Ki67 >10%. Treatments after surgery were not defined by the trial protocol. SET2,3 measures nonproliferation gene expression related to estrogen and progesterone receptors adjusting for a baseline prognostic index that combines clinical tumor and nodal stage and a 4-gene molecular subtype (RNA4) defined by ESR1, PGR, ERBB2 and AURKA. High SET2,3 in a pre-treatment biopsy using cStage information is defined as SET2,3 >1.77. Methods: 379 pts had gene expression data from a research tumor biopsy prior to NET (Agilent 44K microarrays). A bioinformatician blinded to pt treatment and clinical outcomes determined SET2,3. The trial statistician then examined the association between SET2,3 and pharmacodynamic response at 2-4 wks (N=141, Cohort B): Ki67 ≤10% and complete cell cycle arrest (CCCA Ki67 ≤2.7%); pathologic outcomes in pts who completed NET: ypStage 0/1 (N=329, Cohorts A&B), PEPI-0 rate (N=155, Cohort B); and event-free survival (EFS) post-registration (N=244, Cohorts A&B). We used Fisher’s exact tests to assess whether responses, and Cox modeling to evaluate whether EFS, differed with respect to SET2,3 status. Results: High SET2,3 in 48% of pts (183/379) was associated with older age (median: 66 vs 63 years; p=0.012); cStage II (95% vs 75%; p <0.001); and pre-NET Ki67 ≤10% (37% vs 20%; p< 0.001) in pts with low SET2,3. In Cohort B, pts with high SET2,3 had a higher rate of pharmacodynamic response in their tumor at wk 2-4 than pts with low SET2,3 (Table). In the subset of Cohort B pts with wk 2-4 Ki67 ≤10%, pre-treatment SET2,3 trended numerically higher in pts who achieved PEPI-0 score (p=0.049) but the proportion achieving PEPI-0 did not differ by SET2,3 high/low status (Table). EFS was significantly longer for pts with high SET2,3 than pts with low SET2,3 (HR[H/L]: 0.52; 95% CI: 0.34-0.80; p=0.003). Conclusions: An exploratory analysis of Z1031 data demonstrated that the rate of pharmacodynamic suppression of proliferation by NET at 2-4 wks was greater and EFS was longer for pts with breast cancer expressing high SET2,3 disease than pts with low SET2,3. Support: U10CA180821, U10CA180882, U24CA196171; https://acknowledgments.alliancefound.org ; Clinical trial information: NCT00265759. [Table: see text]
Interaction Between SNP Genotype and Efficacy of Anastrozole and Exemestane in Early‐Stage Breast Cancer
Cairns, Junmei , Shepherd, Lois E. , Goss, Paul E. , Barman, Poulami , Goodnature, Barbara, Weinshilboum, Richard M. , Gao, Huanyao , Wang, Liewei , Ingle, James N. , Kalari, Krishna R. , Ellis, Matthew J. , Carlson, Erin E. , Goetz, Matthew P. , Weinshilboum, Richard M.

Mayo Clinic

Clinical Pharmacology & Therapeutics | May 28, 2021 | Volume: 110 | Issue: 4 | Pages: 1038-1049

10.1002/cpt.2311 | PMID 34048027 Get It

Aromatase inhibitors (AIs) are the treatment of choice for hormone receptor–positive early breast cancer in postmenopausal women. None of the third‐generation AIs are superior to the others in terms of efficacy. We attempted to identify genetic factors that could differentiate between the effectiveness of adjuvant anastrozole and exemestane by examining single‐nucleotide polymorphism (SNP)‐treatment interaction in 4,465 patients. A group of SNPs were found to be differentially associated between anastrozole and exemestane regarding outcomes. However, they showed no association with outcome in the combined analysis. We followed up common SNPs near LY75 and GPR160 that could differentiate anastrozole from exemestane efficacy. LY75 and GPR160 participate in epithelial‐to‐mesenchymal transition and growth pathways, in both cases with SNP‐dependent variation in regulation. Collectively, these studies identified SNPs that differentiate the efficacy of anastrozole and exemestane and they suggest additional genetic biomarkers for possible use in selecting an AI for a given patient.
Assessment of Cumulative Incidence and Severity of Primary Open-Angle Glaucoma Among Participants in the Ocular Hypertension Treatment Study After 20 Years of Follow-up
Heuer, Dale K. , Higginbotham, Eve J. , Parrish, Richard , Khanna, Cheryl L. , Brandt, James D. , Soltau, Joern B., Keltner, John L., Huecker, Julia B., Wilson, Bradley , Gordon, Mae O. , Group, Ocular Hypertension Study, Gedee, Steven J., Esquiabro, Maria, Fabrizio, Matthew J., Patorgis, Charles J., Long, Teresa A., McManus, Paul E., Washington, Chantura, Chang, Peter , Orengo-Nania, Silvia, Leger, April, Kinast, Robert M. , Jones, Emily P., Goldman, Casie, Beck, Allen D. , Costarides, Anastasios P., Leef, Donna, Imami, Nauman R., Darnley-Fisch, Deborah , Crandall, David, Gutkowski, Melanie, Hall, Julianne, Fantin, Aldo, Wells, Judy, Jampel, Henry , Quigley, Harry A., Miller, Rhonda, Kalarn, Sachin , Coleman, Anne L. , Young, Jonathan W., Peterson, Christine A., Giaconi, JoAnn A. , Law, Simon K., Duarte, Pamela B., Wood, Sarah Dougherty , Moroi, Sayoki, Gilbert, Jesse L., Shukairy, Aman, Juzych, Mark S. , Milanovic, Cheryl, O'Grady, John M., Conett, Linda A. Van, Mohay-Ambrus, Judith, Bottorff, Michelle, Bennett, Jeffrey R., Sultze, Jane L., Patel, Dharmendra, Cobb, Steven H., Bhattacharjee, Pompa, Cioffi, George A., Blumberg, Dana M., Moraes, Carlos Gustavo De , Atakulova, Marzhan, Weber, Paul A., Sawchyn, Andrea K., Williams, Demarcus, Bennett, George, Bennett, Lindsay C., Miller-Ellis, Eydie , Sankar, Prithvi S. , Grand-Drossner, Sheri, Piltz‐Seymour, Jody R., Niemczyk, Jane L., Brandt, James D., Lim, Michelle, Balasubramaniam, Saranya C., Baik, Annie K., Arnold, Marisa S., Slight, J. Rigby, Ou, Yvonne , Lamping, Kathleen A., Vitelli, Cheryl L., Ashburn, Frank S., Hardney, Karen S., Schwartz, Arthur L., Weiss, Howard S., Clark, Clete, Bhorade, Anjali M., Lind, John T., Adcock, Eve, Plumb, Kim, Leming, Laura, Dillon, B A, Palmberg, Paul, Hodapp, Elizabeth, Varner, Elizabeth A., Savatovsky, Eleonore , Vandenbroucke, Ruth, Dirkes, Keri , Vega, Suzanne , Hunsicker, Maria, Proudfoot, J. , Dunn, D, Everett, Donald F., Gutowski, Melanie, Fischbach, Ellen, Clark, Karen A., Morris, Patricia A., Quinn, Melanie, Pistorius, Sam, Haertter, Leonard W., Kass, Michael A. , Johnson, Chris A. , Liu, Lei , Miller, J. Philip , Quigley, Harry A. , Group, Ocular Hypertension Study, Patorgis, Charles J., Washington, Chantura, Mansberger, Steven L. , Wells, Judy, Quigley, Harry A., Saeedi, Osamah J. , Hughes, Bret A. , Liebmann, Jeffrey M. , Al‐Aswad, Lama A. , Brandt, James D., Lim, Michelle C., Weinreb, Robert Neal , Smith, Mike A., Feuer, William J. , Zangwill, Linda M. , Morris, Patricia A.

Mayo Clinic

JAMA Ophthalmology | April 17, 2021 | Volume: 139 | Issue: 5 | Pages: 558

10.1001/jamaophthalmol.2021.0341 | PMID 33856434 Get It

Treatment-Related Changes in Left Atrial Structure in Atrial Fibrillation: Findings From the CABANA Imaging Substudy
Rettmann, Maryam E. , Holmes, David R. , Monahan, Kristi H. , Breen, Jerome F., Bahnson, Tristram D. , Mark, Daniel B. , Poole, Jeanne E. , Ellis, Alicia M. , Silverstein, A , Al‐Khalidi, Hussein R. , Lee, Kerry L., Robb, Richard A., Packer, Douglas L. , Investigators, for the CABANA Imaging, Silverstein, Adam P , Mark, Daniel B , Investigators, for the CABANA Imaging

Mayo Clinic

Circulation: Arrhythmia and Electrophysiology | April 13, 2021 | Volume: 14 | Issue: 5 | Pages: No page available

10.1161/circep.120.008540 | PMID 33848199 Get It

Background: The CABANA trial (Catheter Ablation Versus Antiarrhythmic Drug Therapy for Atrial Fibrillation) was a randomized, prospective trial of left atrial catheter ablation versus drug therapy for treatment of atrial fibrillation (AF). As part of CABANA, a prospective imaging substudy was conducted. The main objectives were to describe the patterns of changes in the dimensions of the left atrium and pulmonary veins (PVs), and the relationship between these changes with treatment assignment and clinical outcomes. Methods: Computed tomography or magnetic resonance imaging was acquired at baseline and follow-up in 121 ablation (median follow-up 101 days) and 85 drug patients (median follow-up 97 days). Left atrial volume index, mean PV ostial diameter, and ostial diameters of each PV separately were computed. We examined the relationship between the change from baseline to follow-up with subsequent clinical outcomes (composite of death, disabling stroke, serious bleeding, or cardiac arrest [CABANA primary end point], total mortality or cardiovascular hospitalization, first AF recurrence after the 90-day blanking period, first AF/atrial flutter/atrial tachycardia after the 90-day blanking period) using Cox proportional-hazards models. Results: The median (25th to 75th) change from baseline for left atrial volume index was −7.8 mL/m 2 (−16.4 to 0.2), ablation arm and −3.5 mL/m 2 (−11.4 to 2.6), drug therapy arm. The left atrial volume index decreased in 52.9% of ablation patients versus 40.0% of drug therapy patients. Change for mean PV was −2.7 mm (−4.2 to −1.3) in the ablation arm versus −0.1 mm (−1.5 to 0.8) in the drug therapy arm. Changes in left atrium and PV dimensions had no consistent relationship with the risk of developing the study primary end point. Reductions in left atrial volume index, and in mean PV diameter were associated with decreased risk of AF recurrence. Conclusions: Ablation patients demonstrated more frequent and larger atrial structural changes compared with drug patients. These changes suggest a critical relationship between structural features and AF generation.
Primary Outcome Evaluation of a Next-Generation Left Atrial Appendage Closure Device
Kar, Saibal , Doshi, Shephal K. , Sadhu, Ashish, Horton, Rodney , Osorio, José , Stone, James, Shah, Manish H. , Dukkipati, Srinivas R. , Adler, Stuart W., Kim, Jamie , Wazni, Oussama M. , Price, Mathew J., Holmes, David R. , Shipley, Robert D., Gordon, Nicole, Allocco, Dominic J. , Investigators, On behalf of the PINNACLE FLX, Kar, Saibal , Ellis, Christopher R. , Nair, Devi G , Asch, Federico M. , Reddy, Vivek Y. , Investigators, On behalf of the PINNACLE FLX

Mayo Clinic

Circulation | April 6, 2021 | Volume: 143 | Issue: 18 | Pages: 1754-1762

10.1161/circulationaha.120.050117 | PMID 33820423 Get It

Background: Left atrial appendage (LAA) occlusion provides an alternative to oral anticoagulation for thromboembolic risk reduction in patients with nonvalvular atrial fibrillation. Since regulatory approval in 2015, the WATCHMAN device has been the only LAA closure device available for clinical use in the United States. The PINNACLE FLX study (Protection Against Embolism for Nonvalvular AF Patients: Investigational Device Evaluation of the Watchman FLX LAA Closure Technology) evaluated the safety and effectiveness of the next-generation WATCHMAN FLX LAA closure device in patients with nonvalvular atrial fibrillation in whom oral anticoagulation is indicated, but who have an appropriate rationale to seek a nonpharmaceutical alternative. Methods: This was a prospective, nonrandomized, multicenter US Food and Drug Administration study. The primary safety end point was the occurrence of one of the following events within 7 days after the procedure or by hospital discharge, whichever was later: death, ischemic stroke, systemic embolism, or device- or procedure-related events requiring cardiac surgery. The primary effectiveness end point was the incidence of effective LAA closure (peri-device flow ≤5 mm), as assessed by the echocardiography core laboratory at 12-month follow-up. Results: A total of 400 patients were enrolled. The mean age was 73.8±8.6 years and the mean CHA 2 DS 2 -VASc score was 4.2±1.5. The incidence of the primary safety end point was 0.5% with a 1-sided 95% upper CI of 1.6%, meeting the performance goal of 4.2% ( P <0.0001). The incidence of the primary effectiveness end point was 100%, with a 1-sided 95% lower CI of 99.1%, again meeting the performance goal of 97.0% ( P <0.0001). Device-related thrombus was reported in 7 patients, no patients experienced pericardial effusion requiring open cardiac surgery, and there were no device embolizations. Conclusions: LAA closure with this next-generation LAA closure device was associated with a low incidence of adverse events and a high incidence of anatomic closure. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02702271.
Abstract PD2-10: Validation of a predictive model for potential response to neoadjuvant endocrine therapy (NET) in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC): An ALTERNAT
Leitch, A. Marilyn , Sanati, Souzan , Unzeitig, Gary, Hahn, Olwen, Guenther, Joseph M., Caudle, Abigail S. , Crouch, Erika C., Maluf, Horacio , Tiersten, Amy , Mita, Monica , Razaq, Wajeeha, Dockter, Travis , Zujewski, Jo Anne , Weiss, Anna , Hudis, Clifford A. , Cynthia, X. , Ellis, Matthew J. , Suman, Vera J. , Vij, Kiran R , Hoog, Jeremy , Watson, Mark A. , Dowsett, Mitch , Hieken, Tina J. , Wang, Yang , Winer, Eric P. , Hunt, Kelly K. , Partridge, Ann H. , Carey, Lisa A.

Mayo Clinic

Cancer Research | February 15, 2021 | Volume: 81 | Issue: 4_Supplement | Pages: PD2-10-PD2-10

10.1158/1538-7445.sabcs20-pd2-10 Get It

Abstract Background: NET is offered to postmenopausal patients (pts) with clinical stage 2/3 ER+/HER2- BC to promote breast-conserving surgery. Also limited surgical accessibility during the COVID19 pandemic has increased NET utility. Inability to identify ET-resistant disease at diagnosis risks disease progression (PD) and delays more effective treatments. Dowsett et al. recently demonstrated that baseline levels of ER, progesterone receptor (PR), Ki67 (&gt;15% vs ≤15%), and Ki67 (&gt;10% vs ≤10%) 2-4 weeks (wks) after starting NET may improve appropriate patient (pt) selection for NET (PMC7280290). The ER, PR and Ki67-based prediction model divides pts with primary ER+/HER2- BC into 3 groups for appropriateness for NET: (Group 1) NET is likely to be inappropriate (Allred ER &lt;6 or ER 6 and PgR &lt;6), (Group 2) NET may be appropriate and a biopsy for on-treatment Ki67 analysis may be considered after 2-4 wks of NET (2A: ER 7 or 8 and PgR &lt;6 and 2B: ER 6 or 7 and PgR ≥6) given that on-treatment Ki67 &gt;10% has been associated with worse outcome (PMC5455353), or (Group 3) NET is appropriate (ER 8 and PgR ≥6). The ALTERNATE trial (NCT01953588) randomized postmenopausal women with clinical stage II or III, ER+ (Allred score 6-8)/HER2- BC to receive anastrozole (ANA), fulvestrant (FUL), or ANA + FUL for 6 months, unless Ki67 was &gt;10% on wk 4 or 12 biopsy, in which case pts were triaged to receive neoadjuvant chemotherapy (NCT) or surgery. As previously reported, the ET-sensitive disease (mPEPI 0 plus pCR) rates were similar across the treatment arms and overall 22% (286 of 1,299) pts had Ki67 &gt;10% at wk 4 or 12. The ALTERNATE trial therefore provides a large independent data set to evaluate the NET appropriateness model. Results: Among 1,299 eligible pts randomized to receive 6 months of NET, 214 were excluded due to absent HR Allred score (n=41) or absence of pre-treatment and wk 4 Ki67 determinations (n=173). The proportions of the remaining 1,085 pts in Group 1, 2 and 3 were 1% (n=10), 43% (n= 468), and 56% (n=607), respectively. On-study Ki67 &gt;10% prompting conversion from NET to NCT/Surgery occurred in: Group 1 90% (9 of 10), Group 2 30% (141 of 468), and Group 3 17% (104 of 607) (Table 1). Among the 1,075 pts in Groups 2 and 3, 260 (24%) pts had Ki67 ≤15% at baseline (BL), among whom only 14 (5.4%) had Ki67 &gt;10% at wk 4, compared to 231 of the 815 (28.3%) who had BL Ki67 &gt;15% and subsequent Ki67 &gt;10% at wk 4. 2% of pts who remained on NET due to on-treatment Ki67 &lt;10% had PD. Response and PEPI-0 rates by group will be reported. Conclusion: ALTERNATE trial data support a model whereby levels of ER, PR and Ki67 at diagnosis can be used for the identification of postmenopausal pts with primary ER+/HER2- BC who are appropriate for NET. When baseline ER Allred scores are &gt;6 and Ki67 ≤15%, there is a low likelihood of ET-resistant disease. When BL Ki67 is &gt;15%, ET sensitivity is variable, and on-treatment biopsy for Ki67 may assist in triaging regarding NET appropriateness, particularly given the extremely low local PD rates seen in ALTERNATE when on-treatment Ki67 was &lt;10%. Support: U10CA180821, U10CA180882, U24CA196171, UG1CA189856, U10CA180868 (NRG); NCI BIQSFP, BCRF, Genentech, AstraZeneca. https://acknowledgments.alliancefound.org; Clinical Trials.gov Identifier: NCT01953588 Table 1 Baseline levels of ER, PR, and Ki67 in Relation to Wk 4 Ki67 (N=1,085)BaselineWeek 4GroupNERAllred ScorePRAllred ScoreKi67Ki67 ≤10%N (%)Ki67 &gt;10%N (%)1N=26&lt;6≤15%0 (0%)2 (100%)9 (90)N=86&lt;6&gt;15%1 (12.5%)7 (87.5%)2AN=647 or 8&lt;6≤15%61 (95.3%)3 (4.7%)90 (30.1)N=2357 or 8&lt;6&gt;15%148 (63%)87 (37%)2BN=466 or 7≥6≤15%42 (91.3%)4 (8.7%)51 (30.2)N=1236 or 7≥6&gt;15%76 (61.8%)47 (38.2%)3N=1508≥6≤15%143 (95.3%)7 (4.7%)104 (17.1)N=4578≥6&gt;15%360 (78.8%)97 (21.2%) Citation Format: Matthew J Ellis, Vera Suman, A. Marilyn Leitch, Souzan Sanati, Kiran Vij, Gary W Unzeitig, Jeremy Hoog, Mark Watson, Olwen Hahn, Joseph Guenther, Abigail Caudle, Erika Crouch, Horacio Maluf, Mitch Dowsett, Amy Tiersten, Monica Mita, Wajeeha Razaq, Tina J Hieken, Yang Wang, Travis Dockter, Jo Anne Zujewski, Anna Weiss, Clifford Hudis, Eric P Winer, Kelly Hunt, Ann H Partridge, Cynthia X Ma, Lisa A Carey. Validation of a predictive model for potential response to neoadjuvant endocrine therapy (NET) in postmenopausal women with clinical stage II or III estrogen receptor positive (ER+) and HER2 negative (HER2-) breast cancer (BC): An ALTERNATE trial analysis (Alliance A011106) [abstract]. In: Proceedings of the 2020 San Antonio Breast Cancer Virtual Symposium; 2020 Dec 8-11; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2021;81(4 Suppl):Abstract nr PD2-10.